RxDoctor Payments Data

Neesha Berry, MD

Internal Medicine · Southfield, MINPI 1134320930

Payments from drug & device makers

$544in general payments, 2019–2025

Across 13 payments — averaging $41.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$168
  • Avadel CNS Pharmaceuticals, LLC$118
  • Teva Pharmaceuticals USA, Inc.$70
  • Pfizer$39
  • AstraZeneca$28
  • AbbVie$21
  • plus $100 from 6 others

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$544 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$22,111
Medicare patients
34
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$47,388
EliquisApixaban25$35,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,521
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,671
Atorvastatin Calcium132$1,731
Metoprolol Succinate63$1,440
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,398
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide58$1,170
Losartan Potassium92$1,086
Amlodipine Besylate139$1,086
Omeprazole52$1,000
Albuterol Sulfate HfaAlbuterol Sulfate18$930
Chlorthalidone41$859
Pregabalin12$715
Metformin Hcl46$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$47,38838 claims
PfizerEliquis$39$35,72925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →